Company Overview

Company name: InMed Pharmaceuticals (TSE: IN)
Description: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; NM-088 for the treatment of glaucoma; and IntegraSyn.
Year founded: 1981
Parent company:
Industry: Healthcare | Group: | Code:
Website: www.inmedpharma.com
Employees: 20
City: Vancouver
State: British Columbia
Country: Canada
Region:

Financial Highlights

Start up capital raised (USD Million):
Business status: Generating Revenue
Ownership: Publicly Held
Exchange: TSE
Ticker: IN
Revenue (USD Million): 0,00
Gross profit (USD Million):
Net income (USD Million) -7,87
Enterprise value: 12,15
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period: TTM 1Q2021
Financing Status:
Number of active investors:
Profile last updated: 14-dic-2020
Last known valuation:
Last known valuation date: